WO1990001933A1 - Combinaison d'un antibiotique de quinolone et de steroides pour utilisation ophtalmique locale - Google Patents

Combinaison d'un antibiotique de quinolone et de steroides pour utilisation ophtalmique locale Download PDF

Info

Publication number
WO1990001933A1
WO1990001933A1 PCT/US1989/003648 US8903648W WO9001933A1 WO 1990001933 A1 WO1990001933 A1 WO 1990001933A1 US 8903648 W US8903648 W US 8903648W WO 9001933 A1 WO9001933 A1 WO 9001933A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibiotic
steroid
ciprofloxacin
fluorometholone
rimexolone
Prior art date
Application number
PCT/US1989/003648
Other languages
English (en)
Inventor
Gerald D. Cagle
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Publication of WO1990001933A1 publication Critical patent/WO1990001933A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Definitions

  • the present invention relates to the topical ophthalmic use of antibiotics in combination with anti- inflammatory steroids to treat ophthalmic infections and attendant inflammation of ocular tissue.
  • antibiotics in combination with anti- inflammatory steroids to treat ophthalmic infections and attendant inflammation of ocular tissue.
  • Such combinations are generally known and commercially available in the ophthalmic pharmaceutical art.
  • concerns and expressed reservations in the ophthalmic community about the safety and efficacy of such prior art combinations.
  • quinolone antibiotics such as ciprofloxacin, norfloxacin, oflaxacin, difloxacin, pefloxacin or the like and potent steroids such as dexa ethasone, fluorometholone, fluorometholone acetate, prednisolone, prednisolone acetate, medrysone, betamethasone and rimexolone or the like, including pharmaceutically acceptable salts thereof, meet these
  • SUBSTITUTE SHEET criteria The foregoing antibiotics and steroids are known.
  • a preferred antibiotic is ciprofloxacin.
  • Preferred steroids include dexamethasone and rimexolone; the latter compound is described in U. S. Patent No. 3,947,478, the entire contents of which are hereby incorporated in the present specification by reference.
  • compositions of the present invention are administered topically.
  • the dosage range is 0.001 to 5.0 g/per eye; wherein the cited mass figures present the sum -of the two components, e.g. the steroid and the quinolone antibiotic.
  • the compositions of the present invention can be administered as ointments, solutions, suspensions, or emulsions (dispersions) in a suitable ophthalmic vehicle.
  • compositions for topical administration are preferably formulated as 0.01 to 2.0 percent by weight (figures relate to combined presence of the steroid and quinolone antibiotic) solutions in water at a pH of 4.5 to 8.0. , While the precise regimen is left to the discretion of the clinician, it is recommended that the resulting solution be topically applied by placing one drop in each eye two times a day.
  • ingredients which may be desirable to use in the ophthalmic preparations of the present invention include preservatives, co-solvents and viscosity building agents.
  • Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent icrobial contamination during use. Suitable preservatives include: benzalkoniu chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight. Co-Solvents;
  • the solubility of the components of the present compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition.
  • co- solvents include polysorbate 20, 60, and 80.
  • co- solvents are employed at a level of from 0.01% to 2% by weight.
  • Viscosity increased above that of simple aqueous solutions may be desirable to increase ocular absorption of the active compounds, to decrease variability in dispensing the formulation, to decrease physical separation of components of a suspension or emulsion of the formulation and/or to otherwise improve the ophthalmic formulation.
  • Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
  • Example I The following examples are presented to further i l lus trate repre s entative topical ophthalmic pharmaceutical compositions of the present invention .
  • Example I The following examples are presented to further i l lus trate repre s entative topical ophthalmic pharmaceutical compositions of the present invention .

Abstract

L'invention concerne des compositions pharmaceutiques contenant un antibiotique à base de quinolone, tel que la ciprofloxacine, et un stéroïde tel que le rimexolone, le dexaméthasone, le fluorométholone ou l'acétate de fluorométholone, etc à des fins d'utilisation ophtalmique locale, ainsi qu'un procédé de traitement consistant à administrer lesdites compositions localement sur les tissus oculaires affectés pour combattre une infection ou une inflammation associée.
PCT/US1989/003648 1988-08-26 1989-08-24 Combinaison d'un antibiotique de quinolone et de steroides pour utilisation ophtalmique locale WO1990001933A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23682888A 1988-08-26 1988-08-26
US236,828 1988-08-26

Publications (1)

Publication Number Publication Date
WO1990001933A1 true WO1990001933A1 (fr) 1990-03-08

Family

ID=22891134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003648 WO1990001933A1 (fr) 1988-08-26 1989-08-24 Combinaison d'un antibiotique de quinolone et de steroides pour utilisation ophtalmique locale

Country Status (2)

Country Link
AU (1) AU4201189A (fr)
WO (1) WO1990001933A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2065846A1 (es) * 1993-04-20 1995-02-16 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
EP0659763A2 (fr) * 1993-12-22 1995-06-28 Senju Pharmaceutical Co., Ltd. Esters d'acides quinoline-carboxyliques avec des dérivés 21-pregnanes et compositions bactéricides et antiinflammatoire les contenant
EP0689832A2 (fr) 1994-06-29 1996-01-03 Laboratorios S.A.L.V.A.T., S.A. Préparation antibiotique pour application auriculaire
ES2105971A1 (es) * 1995-08-02 1997-10-16 S A L V A T Lab Sa Composicion antibiotica/antiinflamatoria de aplicacion otica.
WO2000018386A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018387A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018404A1 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018388A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2001022936A1 (fr) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Formulations topiques sous forme de suspension contenant de la ciprofloxacine et de la dexamethasone
WO2001078732A1 (fr) * 2000-04-15 2001-10-25 Fresenius Kabi Deutschland Gmbh Solution pour perfusion stable au stockage a base de ciprofloxacine
WO2002026233A1 (fr) * 2000-09-29 2002-04-04 Fresenius Kabi Deutschland Gmbh Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide
WO2002039993A2 (fr) * 2000-11-15 2002-05-23 Chandavarkar Mohan A Medicament combine
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
WO2003026671A1 (fr) * 2001-09-21 2003-04-03 Alcon, Inc. Procede de traitement de l'infection de l'oreille moyenne
US6605295B1 (en) 1997-07-11 2003-08-12 Bausch & Lomb Incorporated Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
WO2004087043A2 (fr) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Composition ophtalmique stable
WO2008085913A1 (fr) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales
US8227452B2 (en) * 2006-06-01 2012-07-24 Novagali Pharma Sa Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
US8932610B2 (en) 2010-03-01 2015-01-13 Laboratorios Salvat, S.A. Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
US10561607B2 (en) 2014-05-23 2020-02-18 Harrow Ip, Llc Pharmaceutical compositions comprising gels and methods for fabricating thereof
US11439590B2 (en) 2013-07-22 2022-09-13 Novel Drug Solutions Llc Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US11484515B2 (en) * 2017-12-12 2022-11-01 University of Pittsburgh—of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
US11510916B2 (en) 2013-07-22 2022-11-29 Novel Drug Solutions Llc Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4730013A (en) * 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4844902A (en) * 1987-02-17 1989-07-04 Bayer Aktiengesellschaft Topically applicable formulations of gyrase inhibitors in combination with corticosteroids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4730013A (en) * 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4844902A (en) * 1987-02-17 1989-07-04 Bayer Aktiengesellschaft Topically applicable formulations of gyrase inhibitors in combination with corticosteroids

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2065846A1 (es) * 1993-04-20 1995-02-16 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
EP0659763A2 (fr) * 1993-12-22 1995-06-28 Senju Pharmaceutical Co., Ltd. Esters d'acides quinoline-carboxyliques avec des dérivés 21-pregnanes et compositions bactéricides et antiinflammatoire les contenant
EP0659763A3 (fr) * 1993-12-22 1995-12-20 Senju Pharma Co Esters d'acides quinoline-carboxyliques avec des dérivés 21-pregnanes et compositions bactéricides et antiinflammatoire les contenant.
US5599807A (en) * 1993-12-22 1997-02-04 Senju Pharmaceutical Co., Ltd. Steroid derivatives
EP0689832A2 (fr) 1994-06-29 1996-01-03 Laboratorios S.A.L.V.A.T., S.A. Préparation antibiotique pour application auriculaire
EP0689832A3 (fr) * 1994-06-29 1998-03-11 Laboratorios S.A.L.V.A.T., S.A. Préparation antibiotique pour application auriculaire
ES2105971A1 (es) * 1995-08-02 1997-10-16 S A L V A T Lab Sa Composicion antibiotica/antiinflamatoria de aplicacion otica.
US6605295B1 (en) 1997-07-11 2003-08-12 Bausch & Lomb Incorporated Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
US8673902B2 (en) 1998-09-30 2014-03-18 Alcon Pharmaceuticals, Ltd. Method of treating otic infections with moxifloxacin compositions
KR101463243B1 (ko) * 1998-09-30 2014-12-17 알콘 래보레이토리스, 인코퍼레이티드 눈, 귀 및 코 치료용 항생제 조성물
WO2000018388A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018388A3 (fr) * 1998-09-30 2000-06-02 Alcon Lab Inc Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018386A3 (fr) * 1998-09-30 2000-06-08 Alcon Lab Inc Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018387A3 (fr) * 1998-09-30 2000-07-06 Alcon Lab Inc Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
EP2796138B1 (fr) 1998-09-30 2016-08-17 Alcon Pharmaceuticals Limited Compositions antibiotiques pour le traitement de la conjonctivite
US8993636B2 (en) 1998-09-30 2015-03-31 Alcon Pharamceuticals, Ltd. Compositions containing moxifloxacin for treating otic infections
WO2000018404A1 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
EP2796138A1 (fr) * 1998-09-30 2014-10-29 Alcon Pharmaceuticals Limited Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
WO2000018386A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
JP2013018799A (ja) * 1998-09-30 2013-01-31 Alcon Lab Inc 眼、耳および鼻治療用の抗生物質組成物
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
JP2002525317A (ja) * 1998-09-30 2002-08-13 アルコン ラボラトリーズ，インコーポレイテッド 眼、耳および鼻治療用の抗生物質組成物
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
JP2012067141A (ja) * 1998-09-30 2012-04-05 Alcon Lab Inc 眼、耳および鼻治療用の抗生物質組成物
EP2301541A1 (fr) * 1998-09-30 2011-03-30 Alcon, Inc. Compositions antibiotiques destinees au traitement des yeux, oreilles et nez
WO2000018387A2 (fr) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
EP1384478A1 (fr) 1998-09-30 2004-01-28 Alcon, Inc Compositions antibiotiques destinees au traitement des yeux, oreilles et nez
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
EP2269602A1 (fr) * 1998-09-30 2011-01-05 Alcon, Inc. Compositions antibiotiques destinees au traitement des yeux, oreilles et nez
US7671070B2 (en) 1998-09-30 2010-03-02 Alcon, Inc. Method of treating ophthalmic infections with moxifloxacin compositions
WO2001022936A1 (fr) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Formulations topiques sous forme de suspension contenant de la ciprofloxacine et de la dexamethasone
KR100722502B1 (ko) * 1999-09-24 2007-05-28 알콘, 인코퍼레이티드 사이프로플록사신 및 덱사메타손 함유 국소용 현탁제
US6284804B1 (en) 1999-09-24 2001-09-04 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
AU776609B2 (en) * 1999-09-24 2004-09-16 Novartis Ag Topical suspension formulations containing ciprofloxacin and dexamethasone
US6359016B2 (en) 1999-09-24 2002-03-19 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
WO2001078732A1 (fr) * 2000-04-15 2001-10-25 Fresenius Kabi Deutschland Gmbh Solution pour perfusion stable au stockage a base de ciprofloxacine
WO2002026233A1 (fr) * 2000-09-29 2002-04-04 Fresenius Kabi Deutschland Gmbh Solution pour perfusion de ciprofloxacine stable au stockage et a teneur reduite en acide
WO2002039993A2 (fr) * 2000-11-15 2002-05-23 Chandavarkar Mohan A Medicament combine
AU2002216357B2 (en) * 2000-11-15 2006-08-17 Chandavarkar, Mohan A Pharmaceutival preparations comprising corticosteroids and antiinfective agents
WO2002039993A3 (fr) * 2000-11-15 2003-02-27 Mohan A Chandavarkar Medicament combine
US8846650B2 (en) 2001-09-21 2014-09-30 Novartis Ag Method of treating middle ear infections
WO2003026671A1 (fr) * 2001-09-21 2003-04-03 Alcon, Inc. Procede de traitement de l'infection de l'oreille moyenne
US9149486B2 (en) 2001-09-21 2015-10-06 Alcon Pharmaceuticals Ltd Method of treating middle ear infections
US9402805B1 (en) 2001-09-21 2016-08-02 Alcon Pharmaceuticals Ltd. Method of treating middle ear infections
JP2006518769A (ja) * 2003-02-21 2006-08-17 サン・ファーマシューティカル・インダストリーズ・リミテッド 安定な眼科用組成物
WO2004087043A3 (fr) * 2003-02-21 2004-12-16 Sun Pharmaceutical Ind Ltd Composition ophtalmique stable
WO2004087043A2 (fr) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Composition ophtalmique stable
US9192567B2 (en) 2006-06-01 2015-11-24 Santen Sas Method for treating eye disease or conditions affecting the posterior segment of the eye
US8227452B2 (en) * 2006-06-01 2012-07-24 Novagali Pharma Sa Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
WO2008085913A1 (fr) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales
US8932610B2 (en) 2010-03-01 2015-01-13 Laboratorios Salvat, S.A. Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
US11439590B2 (en) 2013-07-22 2022-09-13 Novel Drug Solutions Llc Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US11510916B2 (en) 2013-07-22 2022-11-29 Novel Drug Solutions Llc Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US11684570B2 (en) 2013-07-22 2023-06-27 Novel Drug Soultions Llc Pharmaceutical ophthalmic compositions
US10561607B2 (en) 2014-05-23 2020-02-18 Harrow Ip, Llc Pharmaceutical compositions comprising gels and methods for fabricating thereof
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
US11484515B2 (en) * 2017-12-12 2022-11-01 University of Pittsburgh—of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear

Also Published As

Publication number Publication date
AU4201189A (en) 1990-03-23

Similar Documents

Publication Publication Date Title
WO1990001933A1 (fr) Combinaison d'un antibiotique de quinolone et de steroides pour utilisation ophtalmique locale
US5149694A (en) Combination of tobramycin and dexamethasone for topical ophthalmic use
EP0592348B1 (fr) Composition pharmaceutique contenant de la polymyxine-triméthoprine et un agent anti-inflammatoire pour l'utilisation ophthalmique et ototopique
US7560448B2 (en) Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
EP0773022B1 (fr) Composition pharmaceutique pour le traitement de la rhinite, contenant un sympathomimétique et du pantothenol et/ou l'acide pantothénique
US5134124A (en) Use of a statin derivative in the treatment of eye complaints
US4822819A (en) Use of trimoprostil and derivatives in glaucoma therapy
KR970704452A (ko) 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases)
JPS6322021A (ja) 眼圧制御剤
EP0603800A1 (fr) Mélanges de prostaglandines pour la thérapie du glaucome
US5149693A (en) Combination of tobramycin and fluorometholone for topical ophthalmic use
US5489576A (en) Therapeutic agent for hemorrhoidal diseases
US5565492A (en) Prostaglandin combinations in glaucoma therapy
EP0365613B1 (fr) Tobramycine et steroides combines destines a une utilisation ophtalmique topique
US4840798A (en) Astringent gel composition and method for use
CA1049409A (fr) Preparation a usage local contenant un steroide et de la neomycine
US5173507A (en) Prostaglandin combinations in glaucoma therapy
US4822820A (en) Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
JP3328729B2 (ja) 抗緑内障薬剤組成物
US5627209A (en) Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
DE602004008083T2 (de) Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
US5641781A (en) Topical ophthalmic composition comprising a 2-[4-(azolylbutyl)piperazinylmethyl]benzimidazole derivative, in particular for the treatment of allergic conjunctivitis
US5654335A (en) Topical use of ethyl ethacrynate for glaucoma treatment
US3789121A (en) 17{60 ,21-orthobutyrates of 6{60 , 9{60 -difluoro-hydrocortisone and 6{60 , 9{60 -difluoroprednisolone, compositions containing same and the use thereof as anti-inflammatory agents
US4322425A (en) Compositions for treating glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE